- Review
David vs. Goliath: The Structure, Function, and Clinical Prospects of Antibody Fragments
- Adam Bates and
- Christine A. Power
Since the licensing of the first monoclonal antibody therapy in 1986, monoclonal antibodies have become the largest class of biopharmaceuticals with over 80 antibodies currently approved for a variety of disease indications. The development of smalle...

